Q-omics provides the consensus-scored PKN1 profile across patient tissues and cancer cell-line models. PKN1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PKN1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PKN1 protein abundance shows 23,481 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where PKN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PKN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PKN1 survival associations across molecular data types. PKN1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PKN1 RNA expression–survival associations across cancer types. High PKN1 expression shows unfavorable associations in MESO, KICH, LAML and ACC, but favorable associations in HNSC and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PKN1 RNA expression.
This table summarizes PKN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PKN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PKN1 shows higher tumor expression in KIRC, KIRP, COAD, LIHC, HNSC and BRCA. The KIRC box plot shows higher PKN1 RNA expression in tumor versus normal tissue (log2 FC = +1.006, t-test p < 0.001).
This table shows molecular features associated with PKN1 in patient tissues and cancer cell lines. In patient samples, PKN1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PKN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
